Ring in the Changes
Is a bimatoprost-eluting silicone ring a credible alternative to eyedrops?
Mark Hillen |
In patients with glaucoma, every missed dose of topical antiglaucoma therapy means poorer IOL control and faster vision loss. Regimen adherence varies from patient to patient, and missing a dose now and then isn’t the end of the world. But IOP control often requires multiple drops, and the effect of missing doses can quickly add up. Naturally, anything that can support medication compliance will help patients preserve their vision for longer.
One approach that’s currently being investigated is a drug-eluting ocular insert ring (ForSight VISION5), which is placed on the upper and lower fornices of patients’ eyes (Figure 1). Comprised of a 1 mm bimatoprost-silicone matrix, the ring elutes therapeutic drug doses over a 6-month period. Results of a Phase II trial comparing the bimatoprost ring plus artificial tears with a placebo ring plus twice daily timolol 0.5% eyedrops in patients (n=130) with open-angle glaucoma or ocular hypertension controllable by monotherapy are now published (1). In this multicenter, randomized, double-masked trial, the primary efficacy measure was the difference in mean (diurnal) IOP change from baseline.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.